Clinical trials: in Lebanon
Beta Thalassemia
Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia
The purpose of this study is to evaluate the safety and tolerability of HQK-1001 administered daily for 8 weeks in subjects with beta thalassemia intermedia
- Trial name
- NCT00790127
- Testing
- HQK-1001
- Where
- 2 sites in Lebanon, Thailand
- Volunteers
- 21 people
- Sponsor
- HemaQuest Pharmaceuticals Inc.
Myocardial Ischemia, Acute Coronary Syndrome
Trial of Screening for ALOA-IgG AtheroAbzyme Test
This is a trial of screening for ALOA-IgG AtheroAbzyme Test comparing healthy, asymptomatic myocardial ischemic and acute coronary syndrome patients.
- Trial name
- OP512011 (NCT01272986)
- Testing
- ALOA IgG-Elisa, ALOA IgG-AtheroAbzyme
- Where
- Lebanon
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Omicron Pharmaceuticals
Metabolic Disease
Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)
A trial of LaFlavon in Patients with Metabolic Syndrome to Evaluate its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL).
- Trial name
- LaFlavon (NCT01286909)
- Testing
- LaFlavon
- Where
- Lebanon
- Volunteers
- 40 people
- Sponsor
- Omicron Pharmaceuticals
Diabetes Mellitus, Type 2, Acute Myocardial Infarction
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined…
- Trial name
- IONM (NCT00191282)
- Testing
- Insulin lispro, Human insulin isophane suspension (NPH), Insulin glargine
- Where
- 17 sites in Canada, Croatia and 15 more
- Volunteers
- 1,116 people
- Sponsor
- Eli Lilly and Company
Hypertension
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy
Primary Objective: To demonstrate that the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 150/5 mg is superior to that of amlodipine 5 mg monotherapy in lowering systolic blood pressure (SBP) as measured…
- Trial name
- I-COMBINE (NCT00956644)
- Testing
- irbesartan/amlodipine, amlodipine
- Where
- 40 sites in Brazil, Chile and 7 more
- Volunteers
- 406 people
- Sponsor
- Sanofi
Male, Hypogonadism
Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice
This is an observational study with a drug called Nebido, a new testosterone replacement therapy, which is available for the treatment of male hypogonadism.
- Trial name
- IPASS Nebido (NCT00410306)
- Testing
- Testosterone Undecanoate (Nebido, BAY86-5037)
- Where
- 33 sites in Australia, Austria and 31 more
- Volunteers
- 1,493 people
- Sponsor
- Bayer
Smoking Cessation
Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking
The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation.
- Trial name
- NCT00594204
- Testing
- varenicline tartrate (CP-526, 555-18)
- Where
- 42 sites in Brazil, Colombia and 9 more
- Volunteers
- 593 people
- Sponsor
- Pfizer
Hypertension
ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
To compare the antihypertensive efficacy of the combination irbesartan/hydrochlorothiazide (HCTZ) using either a usual or an active elective titration regimen.
- Trial name
- ACTUAL (NCT00708344)
- Testing
- Irbesartan - Hydrochlorothiazide
- Where
- 16 sites in Algeria, Argentina and 14 more
- Volunteers
- 832 people
- Sponsor
- Sanofi
Osteoporosis Postmenopausal
Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
To confirm the non-inferiority of 75 mg risedronate tablets taken on 2 consecutive days per month as compared to 5 mg risedronate tablets taken daily in increasing bone mass in lumbar spine in postmenopausal women with…
- Trial name
- NCT00358176
- Testing
- Risedronate (HMR4003)
- Where
- 11 sites in United States, Argentina and 9 more
- Volunteers
- 1,231 people
- Sponsor
- Sanofi
Major Depressive Disorder
Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months
In usual clinical conditions, depressed patients with no sexual dysfunction, after signing their consent for the dissemination of their clinical information will begin their treatment with any SSRI or a Dual antidepressant as per…
- Trial name
- NCT00561509
- Testing
- SSRIs, Dual antidepressants
- Where
- 57 sites in Austria, China and 11 more
- Volunteers
- 1,626 people
- Sponsor
- Eli Lilly and Company
Myocardial Infarction, Acute ST-Segment Elevation
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after…
- Trial name
- NCT00077792
- Testing
- Enoxaparin sodium (XRP4563)
- Where
- 48 sites in United States, Argentina and 46 more
- Volunteers
- 20,506 people
- Sponsor
- Sanofi
Lupus Erythematosus, Systemic, Lupus Nephritis
Study of LJP 394 in Lupus Patients With History of Renal Disease
The primary purpose of this study is to determine whether abetimus sodium is more effective than placebo in delaying time to renal flare in SLE patients with a history of renal disease.
- Trial name
- ASPEN (NCT00089804)
- Testing
- abetimus sodium (LJP 394), Phosphate-buffered saline
- Where
- 201 sites in United States, Argentina and 28 more
- Volunteers
- 943 people
- Sponsor
- La Jolla Pharmaceutical Company
Pneumonia
Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia
Primary Objective: The primary objective of the study is to demonstrate the non-inferiority in clinical efficacy at the test of cure (TOC) visit planned 5-7 days after treatment completion of levofloxacin 750 mg once daily (od)…
- Trial name
- NCT00253955
- Testing
- Levofloxacin, Piperacillin/Tazobactam
- Where
- 17 sites in Austria, Belgium and 15 more
- Volunteers
- 460 people
- Sponsor
- Sanofi
Sepsis
The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis
Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction.
- Trial name
- NCT00045760
- Testing
- Drotrecogin alfa (activated)
- Where
- 426 sites in United States, Australia and 30 more
- Sponsor
- Eli Lilly and Company